The Catalyst

Most Recent Posts

12.05.12 | By Kaelan Hollon

Below is the latest guest post in our "Part D Perspectives" series, which we'll be hosting through the rest of the year.

Grace Boatright, legislative director of the National Grange, shared her views on Part D and the positive impact it has had on Grange members.

12.05.12 | By Stephanie Fischer

Not surprisingly, PhRMA was not alone in objecting to the one-sided article on clinical trials which was recently featured on the front page of the

12.05.12 | By Jennifer Wall

[caption id="attachment_5026" align="alignleft" width="150" caption="Photo used under Creative Commons from NHSE"][/caption]

12.04.12 | By Scott LaGanga

Today we've got a guest post from Darrell Roberts, Executive Director of Helmets to Hardhats.

12.04.12 | By Kaelan Hollon

Today we've got a guest post from Anne Whitaker, President, North America Pharmaceuticals of Sanofi.

12.04.12 | By Jay Taylor, By Jay Taylor

Now that the election season is behind us, the U.S. trade agenda appears set to heat up. Last week, during a trip to Asia President Obama stressed the importance of the Trans-Pacific Partnership (TPP) - not only for U.S. trade policy but for greater U.S. geopolitical purposes.

12.04.12 | By Jennifer Wall

In November, the President's Council of Advisors on Science and Technology (PCAST) issued a report focusing on what they view as the necessary steps to

11.30.12 | By Scott LaGanga

Earlier this week, the Partnership for Safe Medicines (PSM) officially launched PSM China, the latest international public-private collaboration to help address the growing threat posed by counterfeit drugs. In addition to PhRMA Chairman and Eli Lilly President and CEO Dr.

11.30.12 | By Kaelan Hollon

Today we've got a guest post from Thomas F. Goss, Senior Vice President of Boston Healthcare Associates, Inc.

11.30.12 | By Rick Smith

Yesterday the Congressional Budget Office (CBO) released a report describing revised methodology for estimating the fi

11.30.12

Last week we noticed two new studies that demonstrate the health benefits of communication about innovative medicines to patients. These studies add to the evidence that direct-to-consumer (DTC) advertisements help patients discuss new treatment options with their doctors and nurses.

11.30.12 | By Christian Clymer

In honor of National Diabetes Awareness Month, we want to share with you the story of a recently diagnosed Type II Diabetes patient and her experience with a prescription assistance program:

11.29.12 | By Gretta Stone

This week I'm in Boston attending the Harvard Personalized Medicine Conference.

11.29.12 | By Christian Clymer

Today we've got a guest post from Dr. Murray Stewart, Senior Vice President, Metabolic Pathways and Cardiovascular, Research & Development of GlaxoSmithKline.

11.29.12 | By John Castellani

We have been tackling the misfortune and suffering caused by HIV/AIDS now for more than 30 years.

11.28.12 | By Kaelan Hollon

AFLCIO.org profiled the successful partnership between organized labor and the biopharmaceutical industry as they work together to foster good jobs and help increase access to high-quality affordable health care.

11.28.12 | By Kaelan Hollon

Below is the latest guest post in our "Part D Perspectives" series, which we'll be hosting during the 2013 Medicare Part D Open Enrollment Period (Oct. 12 - Dec. 7).

11.28.12

Few things exemplify the promise, challenges and opportunities confronting the global biopharmaceutical research sector as do efforts to foster biopharma innovation in China.

11.28.12 | By Kaelan Hollon

Today we've got a special guest blog post from Dr. John P. Howe III, M.D., President and CEO of Project HOPE. They're doing some pretty special work in South Africa on diabetes, and I encourage readers to check out their website to learn more.

11.26.12

Clinical trials are a critical part of the development of innovative medicines that deliver life-saving benefits to patients.

Pages